Skip to main content
Top
Published in: Tumor Biology 8/2016

01-08-2016 | Original Article

Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression

Authors: Fengkun Du, Yan Li, Wensheng Zhang, Shubha P. Kale, Harris McFerrin, Ian Davenport, Guangdi Wang, Elena Skripnikova, Xiao-Lin Li, Nathan J. Bowen, Leticia B McDaniels, Yuan-Xiang Meng, Paula Polk, Yong-Yu Liu, Qian-Jin Zhang

Published in: Tumor Biology | Issue 8/2016

Login to get access

Abstract

Patients with advanced epithelial ovarian cancer often experience disease recurrence after standard therapies, a critical factor in determining their five-year survival rate. Recent reports indicated that long-term or short-term survival is associated with varied gene expression of cancer cells. Thus, identification of novel prognostic biomarkers should be considered. Since the mouse genome is similar to the human genome, we explored potential prognostic biomarkers using two groups of mouse ovarian cancer cell lines (group 1: IG-10, IG-10pw, and IG-10pw/agar; group 2: IG-10 clones 2, 3, and 11) which display highly and moderately aggressive phenotypes in vivo. Mice injected with these cell lines have different survival time and rates, capacities of tumor, and ascites formations, reflecting different prognostic potentials. Using an Affymetrix Mouse Genome 430 2.0 Array, a total of 181 genes were differentially expressed (P < 0.01) by at least twofold between two groups of the cell lines. Of the 181 genes, 109 and 72 genes were overexpressed in highly and moderately aggressive cell lines, respectively. Analysis of the 109 and 72 genes using Ingenuity Pathway Analysis (IPA) tool revealed two cancer-related gene networks. One was associated with the highly aggressive cell lines and affiliated with MYC gene, and another was associated with the moderately aggressive cell lines and affiliated with the androgen receptor (AR). Finally, the gene enrichment analysis indicated that the overexpressed 89 genes (out of 109 genes) in highly aggressive cell lines had a function annotation in the David database. The cancer-relevant significant gene ontology (GO) terms included Cell cycle, DNA metabolic process, and Programmed cell death. None of the genes from a set of the 72 genes overexpressed in the moderately aggressive cell lines had a function annotation in the David database. Our results suggested that the overexpressed MYC and 109 gene set represented highly aggressive ovarian cancer potential biomarkers while overexpressed AR and 72 gene set represented moderately aggressive ovarian cancer potential biomarkers. Based on our knowledge, the current study is first time to report the potential biomarkers relevant to different aggressive ovarian cancer. These potential biomarkers provide important information for investigating human ovarian cancer prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342:257–63.CrossRefPubMed Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342:257–63.CrossRefPubMed
3.
4.
go back to reference du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.CrossRefPubMed du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.CrossRefPubMed
5.
go back to reference Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.CrossRefPubMed Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.CrossRefPubMed
6.
go back to reference Skirnisdottir IA, Sorbe B, Lindborg K, Seidal T. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:236–44.CrossRefPubMed Skirnisdottir IA, Sorbe B, Lindborg K, Seidal T. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21:236–44.CrossRefPubMed
7.
go back to reference Nikas JB, Boylan KL, Skubitz AP, Low WC. Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Informat. 2011;10:233–47.CrossRef Nikas JB, Boylan KL, Skubitz AP, Low WC. Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Informat. 2011;10:233–47.CrossRef
8.
go back to reference Kamieniak MM, Rico D, Milne RL, Munoz-Repeto I, Ibanez K, Grillo MA, et al. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol. 2015;9:422–36.CrossRefPubMed Kamieniak MM, Rico D, Milne RL, Munoz-Repeto I, Ibanez K, Grillo MA, et al. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol. 2015;9:422–36.CrossRefPubMed
9.
go back to reference Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–91.CrossRefPubMed Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–91.CrossRefPubMed
10.
go back to reference Li XL, Zhang DQ, Wang D, Knight DS, Yin L, Bao J, et al. In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicity. Tumour Biol. 2008;29:359–70.CrossRefPubMed Li XL, Zhang DQ, Wang D, Knight DS, Yin L, Bao J, et al. In vivo survivors of transformed mouse ovarian surface epithelial cells display diverse phenotypes for gene expression and tumorigenicity. Tumour Biol. 2008;29:359–70.CrossRefPubMed
11.
go back to reference Urzua U, Frankenberger C, Gangi L, Mayer S, Burkett S, Munroe DJ. Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. Tumour Biol. 2005;26:236–44.CrossRefPubMed Urzua U, Frankenberger C, Gangi L, Mayer S, Burkett S, Munroe DJ. Microarray comparative genomic hybridization profile of a murine model for epithelial ovarian cancer reveals genomic imbalances resembling human ovarian carcinomas. Tumour Biol. 2005;26:236–44.CrossRefPubMed
12.
go back to reference D’Andrilli G, Giordano A, Bovicelli A. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open Clin Cancer J. 2008;2:7–12.CrossRefPubMed D’Andrilli G, Giordano A, Bovicelli A. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open Clin Cancer J. 2008;2:7–12.CrossRefPubMed
13.
go back to reference D’Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res. 2004;10:8132–41.CrossRefPubMed D’Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res. 2004;10:8132–41.CrossRefPubMed
14.
go back to reference Saldanha SN, Tollefsbol TO. Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol. 2014;229:393–406.CrossRefPubMed Saldanha SN, Tollefsbol TO. Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol. 2014;229:393–406.CrossRefPubMed
15.
go back to reference Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer. 2009;19:992–7.CrossRefPubMed Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer. 2009;19:992–7.CrossRefPubMed
16.
17.
go back to reference Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008;18:538–48.CrossRefPubMed Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008;18:538–48.CrossRefPubMed
18.
go back to reference Yin F, Liu X, Li D, Wang Q, Zhang W, Li L. Tumor suppressor genes associated with drug resistance in ovarian cancer (review). Oncol Rep. 2013;30:3–10.PubMed Yin F, Liu X, Li D, Wang Q, Zhang W, Li L. Tumor suppressor genes associated with drug resistance in ovarian cancer (review). Oncol Rep. 2013;30:3–10.PubMed
19.
go back to reference Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M, et al. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep. 2007;17:505–16.PubMed Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M, et al. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep. 2007;17:505–16.PubMed
20.
go back to reference Baserga R, Porcu P, Sell C. Oncogenes, growth factors and control of the cell cycle. Cancer Surv. 1993;16:201–13.PubMed Baserga R, Porcu P, Sell C. Oncogenes, growth factors and control of the cell cycle. Cancer Surv. 1993;16:201–13.PubMed
21.
go back to reference Zimonjic DB, Popescu NC. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Int J Oncol. 2012;41:393–406.PubMedPubMedCentral Zimonjic DB, Popescu NC. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Int J Oncol. 2012;41:393–406.PubMedPubMedCentral
22.
go back to reference Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Leon J. MYC oncogene in myeloid neoplasias. Clin Transl Oncol. 2013;15:87–94.CrossRefPubMed Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, Leon J. MYC oncogene in myeloid neoplasias. Clin Transl Oncol. 2013;15:87–94.CrossRefPubMed
23.
go back to reference Tamai Y, Taketo M, Nozaki M, Seldin MF. Mouse Elk oncogene maps to chromosome X and a novel Elk oncogene (Elk3) maps to chromosome 10. Genomics. 1995;26:414–6.CrossRefPubMed Tamai Y, Taketo M, Nozaki M, Seldin MF. Mouse Elk oncogene maps to chromosome X and a novel Elk oncogene (Elk3) maps to chromosome 10. Genomics. 1995;26:414–6.CrossRefPubMed
24.
go back to reference Pickeral OK, Li JZ, Barrow I, Boguski MS, Makalowski W, Zhang J. Classical oncogenes and tumor suppressor genes: a comparative genomics perspective. Neoplasia. 2000;2:280–6.CrossRefPubMedPubMedCentral Pickeral OK, Li JZ, Barrow I, Boguski MS, Makalowski W, Zhang J. Classical oncogenes and tumor suppressor genes: a comparative genomics perspective. Neoplasia. 2000;2:280–6.CrossRefPubMedPubMedCentral
25.
go back to reference Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69:111–7.CrossRefPubMed Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69:111–7.CrossRefPubMed
26.
go back to reference Agren M, Kogerman P, Kleman MI, Wessling M, Toftgard R. Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene. 2004;330:101–14.CrossRefPubMed Agren M, Kogerman P, Kleman MI, Wessling M, Toftgard R. Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene. 2004;330:101–14.CrossRefPubMed
27.
go back to reference Enrietto PJ. The myc oncogene in avian and mammalian carcinogenesis. Cancer Surv. 1987;6:85–99.PubMed Enrietto PJ. The myc oncogene in avian and mammalian carcinogenesis. Cancer Surv. 1987;6:85–99.PubMed
28.
go back to reference Slotman BJ, Nauta JJ, Rao BR. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer. 1990;66:740–4.CrossRefPubMed Slotman BJ, Nauta JJ, Rao BR. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer. 1990;66:740–4.CrossRefPubMed
29.
go back to reference Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001;20:6617–26.CrossRefPubMed Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene. 2001;20:6617–26.CrossRefPubMed
30.
go back to reference Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A. 2004;101:2434–9.CrossRefPubMedPubMedCentral Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A. 2004;101:2434–9.CrossRefPubMedPubMedCentral
31.
go back to reference Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Oncol Rep. 2007;18:1347–56.PubMed Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Oncol Rep. 2007;18:1347–56.PubMed
32.
go back to reference Morgenbesser SD, DePinho RA. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin Cancer Biol. 1994;5:21–36.PubMed Morgenbesser SD, DePinho RA. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin Cancer Biol. 1994;5:21–36.PubMed
33.
go back to reference Watson JV, Curling OM, Munn CF, Hudson CN. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol. 1987;28:137–50.CrossRefPubMed Watson JV, Curling OM, Munn CF, Hudson CN. Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer. Gynecol Oncol. 1987;28:137–50.CrossRefPubMed
34.
go back to reference Somay C, Grunt TW, Mannhalter C, Dittrich C. Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells. Br J Cancer. 1992;66:93–8.CrossRefPubMedPubMedCentral Somay C, Grunt TW, Mannhalter C, Dittrich C. Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells. Br J Cancer. 1992;66:93–8.CrossRefPubMedPubMedCentral
35.
go back to reference Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, et al. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res. 1995;15:1501–10.PubMed Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, et al. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res. 1995;15:1501–10.PubMed
36.
go back to reference Kuhnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987;26:393–7.CrossRefPubMed Kuhnel R, de Graaff J, Rao BR, Stolk JG. Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987;26:393–7.CrossRefPubMed
37.
go back to reference Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res. 1998;17:231–7.PubMed Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res. 1998;17:231–7.PubMed
38.
go back to reference Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol. 1997;66:250–4.CrossRefPubMed Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol. 1997;66:250–4.CrossRefPubMed
39.
go back to reference Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A. 1999;96:5722–7.CrossRefPubMedPubMedCentral Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A. 1999;96:5722–7.CrossRefPubMedPubMedCentral
40.
go back to reference Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.CrossRefPubMedPubMedCentral Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res. 2010;3:14.CrossRefPubMedPubMedCentral
41.
go back to reference Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis. PLoS One. 2013;8:e56381.CrossRefPubMedPubMedCentral Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, et al. Overexpression of CDCA2 in human squamous cell carcinoma: correlation with prevention of G1 phase arrest and apoptosis. PLoS One. 2013;8:e56381.CrossRefPubMedPubMedCentral
42.
go back to reference de Bruin A, Maiti B, Jakoi L, Timmers C, Buerki R, Leone G. Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem. 2003;278:42041–9.CrossRefPubMed de Bruin A, Maiti B, Jakoi L, Timmers C, Buerki R, Leone G. Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem. 2003;278:42041–9.CrossRefPubMed
43.
go back to reference Liebermann DA, Hoffman B. Prostate cancer: JunD, Gadd45a and Gadd45g as therapeutic targets. Cell Cycle. 2011;10:3428.CrossRefPubMed Liebermann DA, Hoffman B. Prostate cancer: JunD, Gadd45a and Gadd45g as therapeutic targets. Cell Cycle. 2011;10:3428.CrossRefPubMed
44.
go back to reference Brooks WS, Helton ES, Banerjee S, Venable M, Johnson L, Schoeb TR, et al. G2E3 is a dual function ubiquitin ligase required for early embryonic development. J Biol Chem. 2008;283:22304–15.CrossRefPubMedPubMedCentral Brooks WS, Helton ES, Banerjee S, Venable M, Johnson L, Schoeb TR, et al. G2E3 is a dual function ubiquitin ligase required for early embryonic development. J Biol Chem. 2008;283:22304–15.CrossRefPubMedPubMedCentral
Metadata
Title
Highly and moderately aggressive mouse ovarian cancer cell lines exhibit differential gene expression
Authors
Fengkun Du
Yan Li
Wensheng Zhang
Shubha P. Kale
Harris McFerrin
Ian Davenport
Guangdi Wang
Elena Skripnikova
Xiao-Lin Li
Nathan J. Bowen
Leticia B McDaniels
Yuan-Xiang Meng
Paula Polk
Yong-Yu Liu
Qian-Jin Zhang
Publication date
01-08-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4518-4

Other articles of this Issue 8/2016

Tumor Biology 8/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine